Alpha-synuclein vaccine with 100% immunogenicity in early Parkinson's, but ~3 quarters of cash left to prove clinical benefit

AC Immune is a clinical-stage biotech company developing a therapeutic vaccine for early Parkinson's disease that has shown strong immune responses but has not yet demonstrated clinical benefit.

AC Immune's lead bet is ACI-7104, a therapeutic vaccine targeting alpha-synuclein aggregation in early Parkinson's disease, a stage where slowing neurodegeneration could matter most. The thesis turns on whether week-100 Part 1 data show meaningful clinical or biomarker evidence of disease modification, converting immunogenicity into a credible efficacy signal. With roughly $28M cash and ~$8M quarterly burn, the company has approximately three quarters of runway, making financing a parallel risk to the data itself.